Please login to the form below

Not currently logged in
Email:
Password:

Novasep names Michel Spagnol CEO

Joins contract manufacturing firm from Shasun

Novasep Michel Spagnol Novasep has appointed Michel Spagnol as its new president and CEO, succeeding Patrick Glaser who returns to the US.

Spagnol joins French contract manufacturing firm Novasep from Shasun, where he was president and chief technology officer.

Prior to Shasun, Spagnol spent his career at Rhodia in Lyon, France and New Jersey, US, where he progressed first in technical R&D leadership roles and subsequently transitioned to business development as sales and marketing vice president of Rhodia Pharma Solutions.  

He joins Novasep as the company looks to expand through investments in its manufacturing capabilities in both France and China.

“His track record in delivering customer driven solutions, his international and scientific background coupled with his extensive management experience, longstanding knowledge and relationships in the pharmaceutical industry will be strong assets for the company,” said Roger-Marc Nicoud, founder and non-executive chairman of the board of Novasep.

9th July 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics